Emerging challenges in cell therapy manufacturing: Solutions from monoclonal antibodies

BioProcess International

Volumn 10, Issue SUPPL. 3, 2012, Pages 4-7

  Jones, Susan Dana ^a   McKee, Susan ^b   Levine, Howard L ^a  

^a BioProcess Technology Consultants Inc   (United States)

^b Angel Biotechnology Plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; OKT 3; RECOMBINANT PROTEIN; VEDOTIN;

ANTIBODY TITER; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOREACTOR; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL THERAPY; CELL TRANSPLANTATION; CHO CELL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIABETES MELLITUS; DONOR; DOWNSTREAM PROCESSING; FOOD AND DRUG ADMINISTRATION; GENETIC MANIPULATION; GOOD MANUFACTURING PRACTICE; GROWTH RATE; HEART FAILURE; HOST CELL; HUMAN; HUMAN GENOME; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMPLANTATION; IN VIVO STUDY; KIDNEY GRAFT REJECTION; MAMMAL CELL; METHODOLOGY; MULTIPLE SCLEROSIS; MULTIPOTENT STEM CELL; PHENOTYPE; PLURIPOTENT STEM CELL; PURIFICATION; RHEUMATOID ARTHRITIS; SCALE UP; SHORT SURVEY; SPINAL CORD INJURY; STROKE; UNITED STATES;

EID: 84863539138     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Seattle Genetics; www.adcetris.com/home.php. Accessed 1 February 2012.
2. Ecker D et al. The State of Mammalian Cell Culture Biomanufacturing. BioProcess Technology Consultants, Inc. Woburn, MA; 12 December 2011; www.bptc.com/reports.php.
3. IMS Health Inc. Total Unaudited and Audited Global Pharmaceutical Market, 2003-2010. IMS Health, Inc., Norwalk, CT; 2011 March (cited 7 October 2011); www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Total-Market-2003-2010.pdf.
4. Bersenev A. Roadblocks for Cell Therapy Trials. 2010 June (cited 2012 January); http://hematopoiesis.info/2010/06/05/roadblocks-for-cell-therapy- clinical-trials.
5. FDA (CBER and CDER). Guidance for Industry: Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products. July 1997; www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm124805.pdf.
6. Kohler G, Milstein C. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517) 1975: 495-497.
7. Adamson SR. The Role of Technology and Science in Manufacturing Economics. Presented at IBC Antibody Development and Production Conference 28 February-2 March 2007; San Diego, CA.
8. Butler M. Animal Cell Cultures: Recent Achievements and Perspectives in the Production of Biopharmaceuticals. Appl. Microbiol. Biotechnol. 68(3) 2005: 283-291. (Pubitemid 41159998)
9. European Medicines Agency. Reflection Paper on Stem Cell-Based Medicinal Products. EMA/CAT/571134/2009; www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/02/WC500101692.pdf.